Laboratory Corporation of America Holdings ($LH) Stock Forecast: Down 2.5% Today

What is Laboratory Corporation of America Holdings?

Labcorp (LH) is a leading healthcare company that experienced a significant bearish movement in the market today.

Why is Laboratory Corporation of America Holdings going down?

LH stock is down 2.5% on Apr 23, 2026 14:41

• The bearish movement in Labcorp's stock may be due to profit-taking by investors following a recent surge in the stock price.
• The acquisition of Labcorp shares by M&T Bank Corp is believed to have had an impact on market sentiment, resulting in some selling pressure.
• Despite the market decline, Labcorp's introduction of a new diagnostic test for ovarian cancer treatment demonstrates the company's dedication to innovation and expanding its product offerings, which could potentially benefit its long-term growth prospects.
• Investors are likely keeping a close eye on Labcorp's upcoming earnings release for more insights into the company's financial performance and future outlook.

LH Price Chart

LH Technical Analysis

LH News

Labcorp (LH) to Release Earnings on Thursday

Labcorp (LH) is scheduled to release its Q1 2026 earnings before market open on Thursday, April 30th. Analysts anticipate earnings of $4.10 per share and revenue of $3.5125 billion, with the company having previously beaten EPS consensus in the prior quarter. Labcorp also recently announced a quarterly dividend of $0.72 per share, and analysts maintain a "Moderate Buy" rating with an average price target of $307.20.

https://www.marketbeat.com/instant-alerts/labcorp-lh-to-release-earnings-on-thursday-2026-04-23/

Quest Diagnostics Incorporated (NYSE:DGX) Q1 2026 Earnings Call Transcript

Quest Diagnostics (NYSE:DGX) reported strong Q1 2026 results, exceeding revenue and EPS expectations due to broad-based organic growth and strategic collaborations. The company raised its full-year guidance, emphasizing the success of advanced diagnostics, consumer health initiatives, and productivity gains from automation and AI. Discussions also covered the M&A environment and the potential impact of PAMA and CRUSH RFI on Medicare rates and fraud prevention.

https://www.insidermonkey.com/blog/quest-diagnostics-incorporated-nysedgx-q1-2026-earnings-call-transcript-1743829/

Labcorp launches diagnostic test for ovarian cancer treatment By Investing.com

Labcorp has announced the nationwide availability of Agilent Technologies' FDA-approved PD-L1 IHC 22C3 pharmDx diagnostic test. This test identifies patients with platinum-resistant ovarian cancer who are eligible for Merck's KEYTRUDA treatment. The company, which has seen its shares rise 25% over the past year, participated in an Early Validation Program to ensure rapid availability of the diagnostic.

https://za.investing.com/news/company-news/labcorp-launches-diagnostic-test-for-ovarian-cancer-treatment-93CH-4225157

Labcorp Holdings Inc. $LH Shares Acquired by M&T Bank Corp

M&T Bank Corp significantly increased its stake in Labcorp Holdings Inc. (NYSE:LH) by 1,854.7% during the fourth quarter, now owning 256,653 shares valued at over $64 million. Several other institutions also raised their positions in Labcorp, which currently holds a "Moderate Buy" rating with a consensus target price of $307.20. Company insiders have recently sold shares, while analysts have issued various ratings and price target adjustments.

https://www.marketbeat.com/instant-alerts/filing-labcorp-holdings-inc-lh-shares-acquired-by-mt-bank-corp-2026-04-22/

New lab test helps doctors identify ovarian cancer patients for KEYTRUDA

Labcorp has announced the nationwide availability of Agilent's FDA-approved PD-L1 IHC 22C3 pharmDx, a companion diagnostic for identifying platinum-resistant ovarian cancer patients eligible for Merck's KEYTRUDA therapies. This diagnostic helps clinicians identify patients who may benefit from these new treatment options because approximately 80% of ovarian cancer patients experience recurrence and resistance to platinum-based chemotherapy. Labcorp's participation in Agilent's Early Validation Program ensured a rapid rollout of this critical diagnostic test.

https://www.stocktitan.net/news/LH/labcorp-launches-fda-approved-companion-diagnostic-to-identify-o7w9qp7nvych.html

Trending Today

Fiverr International Ltd. ($FVRR) Stock Forecast: Down 5.2% Today

Roku Inc. ($ROKU) Stock Forecast: Down 5.1% Today

Upwork Inc. ($UPWK) Stock Forecast: Down 5.4% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Down 5.0% Today

IPG Photonics Corporation ($IPGP) Stock Forecast: Up 9.8% Today

Paycom Software Inc. ($PAYC) Stock Forecast: Down 5.0% Today

Charter Communications Inc. ($CHTR) Stock Forecast: Down 5.1% Today

NASDAQ-100 ($NDX) Index Forecast: Up 0.3% Today

Zillow Group Inc. ($Z) Stock Forecast: Down 5.2% Today

The Trade Desk Inc ($TTD) Stock Forecast: Down 5.0% Today

Laboratory Corporation of America Holdings Price History

23.03.2026 - LH Stock was down 2.5%

• The bearish movement in Labcorp's stock may be due to profit-taking by investors following a recent surge in the stock price.
• The acquisition of Labcorp shares by M&T Bank Corp is believed to have had an impact on market sentiment, resulting in some selling pressure.
• Despite the market decline, Labcorp's introduction of a new diagnostic test for ovarian cancer treatment demonstrates the company's dedication to innovation and expanding its product offerings, which could potentially benefit its long-term growth prospects.
• Investors are likely keeping a close eye on Labcorp's upcoming earnings release for more insights into the company's financial performance and future outlook.

18.01.2026 - LH Stock was up 5.8%

• Labcorp's target price was raised to $326 by Baird, maintaining an "Outperform" rating, reflecting positive sentiment.
• Labcorp reported strong Q4 and full-year 2025 earnings, with an optimistic 2026 outlook driven by strategic priorities and upbeat profit forecasts.
• JPMorgan adjusted Labcorp's price target to $330, maintaining an "Overweight" rating, following the company's positive Q4 results and 2026 guidance.
• The bullish movement could be attributed to the company's strong financial performance, positive analyst ratings, and strategic growth initiatives, including the launch of an FDA-cleared Alzheimer's blood test.

02.01.2026 - LH Stock was down 1.0%

• Labcorp Holdings recently extended its receivables facility and included a $125 million accordion feature, enhancing financial flexibility. However, this positive development did not significantly influence market activity.
• Thrivent Financial for Lutherans raised its stake in Labcorp Holdings, indicating strong investor confidence, though the stock continued to trend bearishly.
• Speculation about Labcorp Holdings being undervalued, with suggestions of a fair value of $300.06 per share, could be influencing the bearish movement as investors exercise caution.
• Guardant Health's FDA approval for its liquid biopsy for colorectal cancer may have redirected some attention and investments from Labcorp Holdings, resulting in a negative impact on its market performance.

10.03.2026 - LH Stock was down 5.0%

• Labcorp's bearish movement today could be attributed to profit-taking by investors following a recent strong performance in the stock.
• The upcoming first-quarter financial results announcement may have led to some uncertainty and caution among investors, prompting a sell-off.
• Despite the bearish trend, Labcorp's strategic shifts towards specialized testing and AI efficiencies indicate a long-term positive outlook for the company, potentially attracting investors seeking resilient companies in the biopharma services sector.
• The margin boost from divestitures by competitors like Charles River Labs could also be impacting Labcorp's stock performance, as investors assess the competitive landscape in the industry.

17.01.2026 - LH Stock was down 1.1%

• Despite reporting strong earnings and an optimistic annual profit forecast, Labcorp's stock faced downward pressure.
• The market's reaction may have been influenced by Labcorp's fourth-quarter revenue falling short of projections, despite adjusted earnings per share beating expectations.
• Investor concerns about the company's future revenue performance may have driven the sell-off of Labcorp's shares.
• The discrepancy between revenue and earnings results could have prompted profit-taking by investors, contributing to the bearish trend in Labcorp's stock price.